For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is Piracetam?
Piracetam is a synthetic cyclic derivative of gamma-aminobutyric acid (GABA) and the founding member of the racetam family of investigational cognitive compounds. It was synthesized in 1964 by Corneliu E. Giurgea and colleagues at UCB Pharma, initially under the development code UCB6215, and was later marketed in some countries under the name Nootropil. Although its molecular structure is related to GABA, piracetam does not act as a conventional GABA receptor agonist and does not produce the typical sedative or muscle-relaxant effects associated with direct GABAergic drugs. It is generally described as a neuroactive cognitive compound whose effects are most consistently studied in relation to memory, learning, neuronal membrane function, synaptic plasticity, and resistance to certain forms of cellular stress.
Piracetam has been approved or used medically in some jurisdictions for conditions such as cognitive impairment, cortical myoclonus, vertigo, or dyslexia, while it is unapproved or not marketed for these purposes in others, including the United States. The quality of clinical evidence is mixed and varies by indication, study design, dose, and patient population. In healthy adults, evidence for reliable enhancement of intelligence, motivation, or everyday productivity remains limited. Piracetam is frequently used as a reference compound in nootropic research because it has a long pharmacological history, relatively simple oral pharmacokinetics, and a comparatively broad safety record, but "natural," "well tolerated," or "widely studied" does not mean risk-free or universally effective.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Piracetam: a review of pharmacological properties and clinical uses
Winblad, B., 2005, CNS Drug Reviews - Clinical efficacy of piracetam in cognitive impairment: a meta-analysis
Waegemans, T., Wilsher, C. R., Danniau, A., et al., 2002, Dementia and Geriatric Cognitive Disorders - Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders
Malykh, A. G., Sadaie, M. R., 2010, Drugs - Piracetam for dementia or cognitive impairment
Flicker, L., Grimley Evans, J., 2001, Cochrane Database of Systematic Reviews